Bangalore, India - June 17, 2011:
Wipro Technologies, the Global Information Technology, Consulting and Outsourcing business of Wipro Limited (NYSE: WIT) announced a secure cloud-based productized solution called "Wipro Clinical Collaboration Portal", to help its customer base of Drug Development Owners (Sponsors), CROs (Clinical Research Organizations), clinical sites and regulators to significantly improve collaboration capabilities for Multi-region clinical trials. Clinical trials for global studies require close collaboration between partners and regulators across multiple regions to conduct multi-region clinical trials effectively and rapidly. The portal platform will reduce the clinical trial cycle time by 20-30% by speeding up communication and document exchanges between all the stakeholders – the sponsor organization, the staff of the CRO along with clinical site coordinators and principal investigators. This Portal platform can be leveraged as an enterprise level solution to increase efficiency and lower the cost of clinical operations.
There is an intensifying need in the market for a platform that can centralize information, manage financing, facilitate accurate reporting, automatic scheduling and provide the ease of patient recruitment. This need for increased collaboration in clinical trial operation elements, coupled with the need to cater to different styles of recruiting patients, for different therapeutic areas and identifying the best clinical sites that can perform clinical studies, in adherence with the local regulations, has opened up a potential market for a collaboration portal.
This Wipro portal has the capability to better manage all the data required to conduct a clinical trial that makes up the trial master file – which, in the existing clinical trial model, is dominantly paper based in combination with shared folders across geographies.
By enforcing a common SOP (Standard Operating Procedure) across the groups which are involved in clinical trials, the Wipro Clinical Collaboration portal helps them to better adhere to regulatory frameworks such as Good Clinical Practice (GCP) guidelines to avoid any oversight in the trial management process.
"The Wipro Clinical Collaboration "cloud" based portal is supported by Wipro's Rapid Trial framework and very well integrated with leading market products for Electronic Data Capture (EDC), Interactive Voice Recording System (IVRS), Safety, electronic Trial Master File, document management systems and Clinical Trial Management System (CTMS) solutions with a zero CAPEX in a highly compliant, best-in-class system", said R Srinivas Rao, Vice President and Vertical Head – Life Sciences Solutions, Wipro Technologies. He added, "A platform which enables the exchange of documents and communication seamlessly and in compliance with global standards i.e. CFR (Code of Federal Regulations) part 11, while performing the clinical trials really relieves our customers from worrying about the compliance and validation of any solution used in the clinical trial space and helps them focus better on core trial conduct and efficiency."
About Wipro Technologies
Wipro Technologies, the global IT business of Wipro Limited (NYSE:WIT) is a leading Information Technology, Consulting and Outsourcing company, that delivers solutions to enable its clients do business better. Wipro Technologies delivers winning business outcomes through its deep industry experience and a 360 degree view of "Business through Technology" – helping clients create successful and adaptive businesses. A company recognized globally for its comprehensive portfolio of services, a practitioner’s approach to delivering innovation and an organization wide commitment to sustainability, Wipro Technologies has 120,000 employees and clients across 54 countries. For more information, please visit www.wipro.com
Media Contacts: Wipro Technologies
US:
Kathleen Ulrich
Wipro Technologies
+1 (732) 509-1337
kathleen.ulrich@wipro.com
UK:
Rahul Kadavakolu
Wipro Technologies
+44 7920205496
rahul.kadavakolu@wipro.com
Forward-looking and Cautionary Statements
Certain statements in this release concerning our future growth prospects are forward-looking statements, which involve a number of risks, and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in our earnings, revenue and profits, our ability to generate and manage growth, intense competition in IT services, our ability to maintain our cost advantage, wage increases in India, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, restrictions on immigration, our ability to manage our international operations, reduced demand for technology in our key focus areas, disruptions in telecommunication networks, our ability to successfully complete and integrate potential acquisitions, liability for damages on our service contracts, the success of the companies in which we make strategic investments, withdrawal of fiscal governmental incentives, political instability, war, legal restrictions on raising capital or acquiring companies outside India, unauthorized use of our intellectual property, and general economic conditions affecting our business and industry. Additional risks that could affect our future operating results are more fully described in our filings with the United States Securities and Exchange Commission. These filings are available at www.sec.gov. We may, from time to time, make additional written and oral forward-looking statements, including statements contained in the company’s filings with the Securities and Exchange Commission and our reports to shareholders. We do not undertake to update any forward-looking statement that may be made from time to time by us or on our behalf.
